Compare KeyCorp (KEY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs TransMedics Group Inc — how do they compare? KeyCorp trades at $23.16 (market cap $25.17B), while TransMedics Group Inc trades at $73.86 (market cap $2.54B). The key difference: KeyCorp is far larger — about 9.9× TransMedics Group Inc's market cap, and KeyCorp pays a 3.52% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| KEY | TMDX | |
|---|---|---|
Market Cap | $25.17B | $2.54B |
Sector | Financials | Technology |
52-Week High | $23.99 | $150.42 |
52-Week Low | $16.78 | $61.99 |
Dividend Yield | 3.52% | — |
Enterprise Value | — | $2.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $23.26, down 1.23% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Strong fundamentals include a 26.05% net income margin and 10.61% ROE, while valuation metrics show a P/E of 14.45 and P/B of 1.45. Recent corporate actions include consistent quarterly dividends of $0.21 per share and a new $3 billion buyback program announced in July 2026.
KEY presents a compelling investment case with analyst consensus pointing to significant upside (price target $30.50, 31% potential). The combination of earnings momentum, shareholder-friendly capital returns, and improving loan growth supports bullish sentiment. However, risks include potential pressure on net interest margins from Fed policy and competitive challenges in regional banking. The stock's current valuation appears reasonable relative to earnings growth prospects.
TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.
Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
